6273 related articles for article (PubMed ID: 2654950)
1. Pre-clinical models for immunotherapy of melanoma.
Reisfeld RA
Prog Clin Biol Res; 1989; 288():183-93. PubMed ID: 2654950
[No Abstract] [Full Text] [Related]
2. Melanoma: the development of immunoconjugates from a preclinical viewpoint.
Beaumier PL; Morgan AC; Woodhouse CS; Marchitto KS
Immunol Ser; 1990; 53():297-316. PubMed ID: 2100562
[No Abstract] [Full Text] [Related]
3. Potential of genetically engineered monoclonal antibodies for cancer immunotherapy.
Reisfeld RA
Pigment Cell Res; 1992; Suppl 2():109-12. PubMed ID: 1409412
[No Abstract] [Full Text] [Related]
4. Association between induction of anti high molecular weight-melanoma associated antigen (HMW-MAA) immunity with mouse antiidiotypic monoclonal antibody (MoAb) MK2-23 and prolongation of survival in patients with melanoma.
Chen ZJ; Yang H; Liu CC; Mittelman A; Ferrone S
Pigment Cell Res; 1992; Suppl 2():113-22. PubMed ID: 1409413
[No Abstract] [Full Text] [Related]
5. Melanoma antibodies: specificity and interaction with melanoma and cytotoxic T-cells.
Dippold WG; Knuth A; Meyer zum Büschenfelde KH
Behring Inst Mitt; 1984 May; (74):14-8. PubMed ID: 6332614
[TBL] [Abstract][Full Text] [Related]
6. Systemic treatment for renal cell carcinoma: an overview.
Swanson DA
Prog Clin Biol Res; 1990; 350():201-25. PubMed ID: 2201044
[No Abstract] [Full Text] [Related]
7. Cytokine-based therapy for melanoma: pre-clinical studies.
Shurin MR; Kirkwood JM; Esche C
Forum (Genova); 2000; 10(3):204-26. PubMed ID: 11007930
[TBL] [Abstract][Full Text] [Related]
8. Ganglioside antigens expressed by human cancer cells.
Ritter G; Livingston PO
Semin Cancer Biol; 1991 Dec; 2(6):401-9. PubMed ID: 1810468
[TBL] [Abstract][Full Text] [Related]
9. Treatment of human metastatic melanoma with mouse monoclonal antibodies against GD3 ganglioside.
Houghton AN; Bajorin DF; Lonberg M; Chapman P
Prog Clin Biol Res; 1989; 288():383-90. PubMed ID: 2654956
[No Abstract] [Full Text] [Related]
10. Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy.
Reisfeld RA; Gillies SD
J Clin Lab Anal; 1996; 10(3):160-6. PubMed ID: 8731505
[No Abstract] [Full Text] [Related]
11. [Immunotherapy of parenchymal tumors. Recent progress and theoretical considerations].
Marincola F; Smolik L; Annoni F; Holter WD
Minerva Chir; 1988 Jul; 43(13-14):1111-31. PubMed ID: 3054627
[No Abstract] [Full Text] [Related]
12. CTLA-4 blockade: autoimmunity as treatment.
Kapadia D; Fong L
J Clin Oncol; 2005 Dec; 23(35):8926-8. PubMed ID: 16204008
[No Abstract] [Full Text] [Related]
13. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma.
Kim TS; Cohen EP
Cancer Res; 1994 May; 54(10):2531-5. PubMed ID: 8168073
[TBL] [Abstract][Full Text] [Related]
14. Suppression of human melanoma growth in nude mice injected with anti high-molecular-weight melanoma-associated antigen monoclonal antibody 225.28S conjugated to purothionin.
Matsui M; Nakanishi T; Noguchi T; Imai K; Yachi A; Ferrone S
Jpn J Cancer Res; 1985 Feb; 76(2):119-23. PubMed ID: 3920101
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.
Mittelman A; Chen ZJ; Liu CC; Hirai S; Ferrone S
Cancer Res; 1994 Jan; 54(2):415-21. PubMed ID: 8275478
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
17. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
18. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
[TBL] [Abstract][Full Text] [Related]
19. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
[TBL] [Abstract][Full Text] [Related]
20. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes.
Riemer AB; Förster-Waldl E; Brämswig KH; Pollak A; Zielinski CC; Pehamberger H; Lode HN; Scheiner O; Jensen-Jarolim E
Eur J Immunol; 2006 May; 36(5):1267-74. PubMed ID: 16568495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
